Early research (Phase 1)Active Not RecruitingNCT04794699What this trial is testingStudy of IDE397 in Participants With Solid Tumors Harboring MTAP DeletionWho this might be right forSolid Tumor IDEAYA Biosciences 169
Testing effectiveness (Phase 2)Looking for participantsNCT06616987What this trial is testingPrevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast CancerWho this might be right forBreast Cancer Metastatic Yeon Hee Park 40
Large-scale testing (Phase 3)Active Not RecruitingNCT05840211What this trial is testingStudy of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine TherapyWho this might be right forLocally Advanced or Unresectable Metastatic Breast CancerStage IV Breast Cancer Gilead Sciences 654
Large-scale testing (Phase 3)Looking for participantsNCT06312137What this trial is testingAssess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)Who this might be right forNon Small Cell Lung Cancer Merck Sharp & Dohme LLC 780
Testing effectiveness (Phase 2)Enrolling By InvitationNCT07359404What this trial is testingSacituzumab Govitecan Plus Bevacizumab in Metastatic TNBCWho this might be right forAdvanced Breast Cancer YING FAN 60
Testing effectiveness (Phase 2)Study completedNCT04143711What this trial is testingStudy of DF1001 in Patients With Advanced Solid TumorsWho this might be right forSolid Tumor, Adult Dragonfly Therapeutics 270
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07134556What this trial is testingPhase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituzumab Govitecan as 1L Therapy for PD-L1 Positive Advanced TNBCWho this might be right forTriple Negative Breast CancerPDL-1 Positive MedSIR 25
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06462079What this trial is testingSacituzumab Govitecan Combined With Head Radiotherapy for Her2-negative Breast Cancer Brain MetastasesWho this might be right forBrain Metastasis Guangzhou Medical University 43
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07511023What this trial is testingPhase 2 Trial Of Sacituzumab Tirumotecan For Treatment Of Refractory Metastatic Or Unresectable Squamous Cell Carcinoma Of The Anus/RectumWho this might be right forPhase 2Sacituzumab TirumotecanRefractory Metastatic+2 more M.D. Anderson Cancer Center 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT04039230What this trial is testingStudy to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.Who this might be right forBreast Cancer Massachusetts General Hospital 75
Large-scale testing (Phase 3)Looking for participantsNCT06824467What this trial is testingEvaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)Who this might be right forOvarian CancerFallopian Tube CancerPrimary Peritoneal Cancer Merck Sharp & Dohme LLC 770
Testing effectiveness (Phase 2)Looking for participantsNCT04724018What this trial is testingSacituzumab Govitecan Plus EV in Metastatic UCWho this might be right forUrothelial CancerMetastatic Urothelial CarcinomaMetastatic Urothelial Carcinoma of the Renal Pelvis and Ureter+1 more Dana-Farber Cancer Institute 106
Large-scale testing (Phase 3)Looking for participantsNCT06393374What this trial is testingSacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)Who this might be right forTriple-Negative Breast Cancer Merck Sharp & Dohme LLC 1,530
Testing effectiveness (Phase 2)Looking for participantsNCT04559230What this trial is testingSacituzumab Govitecan in Recurrent GlioblastomaWho this might be right forRecurrent Glioblastoma The University of Texas Health Science Center at San Antonio 32
Large-scale testing (Phase 3)Study completedNCT03901339What this trial is testingStudy of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast CancerWho this might be right forMetastatic Breast Cancer Gilead Sciences 543
Testing effectiveness (Phase 2)Looking for participantsNCT07339059What this trial is testingPhase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung CancerWho this might be right forSmall Cell Lung Cancer ( SCLC )Extensive Stage Small Cell Lung Cancer (ES-SCLC) Bindu R Potugari 35
Testing effectiveness (Phase 2)Active Not RecruitingNCT05101096What this trial is testingStudy of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid TumorsWho this might be right forAdvanced Solid TumorMetastatic Triple-Negative Breast CancerHR+/HER2- Metastatic Breast Cancer+1 more Gilead Sciences 135
Testing effectiveness (Phase 2)Study completedNCT05520723What this trial is testingPreventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMEDWho this might be right forTriple Negative Breast CancerBreast CancerAdvanced HR+/HER2- Breast Cancer MedSIR 50
Not applicableNot Yet RecruitingNCT07168083What this trial is testingEfficacy and Safety of Sacituzumab in Patients With OCCC After Immunotherapy ProgressionWho this might be right forOvarian CancerAntibody-drug ConjugatesClear Cell Adenocarcinoma of Ovary Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 22
Testing effectiveness (Phase 2)Active Not RecruitingNCT05675579What this trial is testingA Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)Who this might be right forBreast Cancer M.D. Anderson Cancer Center 27